The Gelatinase Inhibitor ACT-03 Reduces Gliosis in the Rapid Kindling Rat Model of Epilepsy, and Attenuates Inflammation and Loss of Barrier Integrity In Vitro
Accure Therapeutics presented at EAN the improvement of neurodegeneration with ACT-02 in a preclinical study of Parkinson’s disease
Accure Therapeutics presented at ECTRIMS four communications reporting the progress of ACT-01 neuroprotective therapy for Multiple Sclerosis
New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis
